Thromb Haemost 2013; 110(05): 868-875
DOI: 10.1160/TH13-02-0084
Theme Issue Article
Schattauer GmbH

Novel antiplatelet drugs in clinical development

Martin Ungerer
1   AdvanceCor GmbH (previously, Procorde GmbH), Martinsried, Germany
,
Götz Münch
1   AdvanceCor GmbH (previously, Procorde GmbH), Martinsried, Germany
› Author Affiliations
Further Information

Publication History

Received: 01 February 2013

Accepted after major revision: 04 September 2013

Publication Date:
01 December 2017 (online)

Preview

Summary

The clinical value of antiplatelet compounds strongly depends on the benefit-risk balance between their anti-thrombotic effects and the bleeding risk they incur. This ratio is especially important in the treatment of cerebro-vascular disease. Several novel compounds in clinical development hold promise to improve this benefit-risk ratio.